169 related articles for article (PubMed ID: 28827745)
1. Establishing PNB-qPCR for quantifying minimal ctDNA concentrations during tumour resection.
Ehlert T; Tug S; Brahmer A; Neef V; Heid F; Werner C; Jansen-Winkeln B; Kneist W; Lang H; Gockel I; Simon P
Sci Rep; 2017 Aug; 7(1):8876. PubMed ID: 28827745
[TBL] [Abstract][Full Text] [Related]
2. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
3. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
6. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
7. An enzymatic on/off switch-mediated assay for KRAS hotspot point mutation detection of circulating tumor DNA.
Wang QL; Zhou CL; Yin YF; Xiao L; Wang Y; Li K
J Clin Lab Anal; 2020 Aug; 34(8):e23305. PubMed ID: 32207862
[TBL] [Abstract][Full Text] [Related]
8. Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA.
Wood-Bouwens C; Lau BT; Handy CM; Lee H; Ji HP
J Mol Diagn; 2017 Sep; 19(5):697-710. PubMed ID: 28818432
[TBL] [Abstract][Full Text] [Related]
9. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
10. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma.
Sorber L; Zwaenepoel K; Deschoolmeester V; Roeyen G; Lardon F; Rolfo C; Pauwels P
J Mol Diagn; 2017 Jan; 19(1):162-168. PubMed ID: 27865784
[TBL] [Abstract][Full Text] [Related]
12. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
[TBL] [Abstract][Full Text] [Related]
14. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
Sherwood JL; Corcoran C; Brown H; Sharpe AD; Musilova M; Kohlmann A
PLoS One; 2016; 11(2):e0150197. PubMed ID: 26918901
[TBL] [Abstract][Full Text] [Related]
15. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
[No Abstract] [Full Text] [Related]
18. Analysis of Circulating Tumor DNA.
Mithraprabhu S; Spencer A
Methods Mol Biol; 2018; 1792():129-145. PubMed ID: 29797256
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.
Tjensvoll K; Lapin M; Buhl T; Oltedal S; Steen-Ottosen Berry K; Gilje B; Søreide JA; Javle M; Nordgård O; Smaaland R
Mol Oncol; 2016 Apr; 10(4):635-43. PubMed ID: 26725968
[TBL] [Abstract][Full Text] [Related]
20. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
